Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 4, 2013, Pages 412-415

  Urganci, Nafiye ^a   Kalyoncu, Derya ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

childhood; Crohn disease; hepatitis A vaccine; hepatitis B vaccine; inflammatory bowel disease; ulcerative colitis

Indexed keywords

ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; INDETERMINATE COLITIS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; ULCERATIVE COLITIS;

CHILDHOOD, CROHN'S DISEASE, HEPATITIS A VACCINE, HEPATITIS B VACCINE, INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNITY, HUMORAL; INFLAMMATORY BOWEL DISEASES; MALE; PROSPECTIVE STUDIES; VACCINES, DNA; VACCINES, INACTIVATED;

HEPATITIS A VIRUS;

EID: 84875831607     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31827dd87d     Document Type: Article

References (37)

1. Biancone L, Pavia M, Blanco GD, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94.
2. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
3. Chevaux J-B, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010;16:916-24.
4. Rahier JF, Ben-Horin S, Chowers Y, et al. on behalf of the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
5. Cunningham M, Foster GR. What to do about hepatitis B and hepatitis C in patients with IBD, in clinical dilemmas. In: Irving PM, Siegel CA, Rampton DS, eds. Inflammatory Bowel Disease: New Challenges. 2nd ed. et al. Oxford, UK: Wiley-Blackwell; 2011.
6. Tolentino YF, Fogaca HS, Zaltman C, et al. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho University Hospital. World J Gastroenterol 2008;14:3201-6.
7. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009;15:1410-6.
8. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:677-92.
9. Crawford NW, Catto-Smith AG, Oliver MR, et al. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2011;11:87.
10. Rahier JF, Yazdanpanah Y, Colombel JF, et al. The European (ECCO) consensus on infection in IBD: what does it change for the clinician? Gut 2009;58:1313-5.
11. Hou JK, Velayos F, Terrault N, et al. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010;16:925-32.
12. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:619-33.
13. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
14. Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1117-24.
15. Moses J, Alkhouri N, Shannon A, et al. Response to hepatitis Avaccine in children with inflammatory bowel disease receiving infliximab. Inflamm Bowel Dis 2011;17:E160.
16. Altunöz ME, Senateş E, Yeşil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012;57:1039-44.
17. Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012;107:133-8.
18. Vida Pérez L, Gómez Camacho F, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009;132:331-5.
19. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
20. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastro-enterol 2010;105:2085-92.
21. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21.
22. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
23. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010;49:1815-27.
24. Ertekin V, Selimoglu MA, Altinkaynak S. Sero-epidemiology of hepatitis B infection in an urban paediatric population in Turkey. Public Health 2003;117:49-53.
25. Alper CA. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet 1995;12:171-81.
26. Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNAvaccines. Clin Ther 2001;23:392-403.
27. Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007;44:431-5.
28. Noh KW, Poland GA, Murray JA. Hepatitis B nonresponse and celiac disease. Am J Gastroenterol 2003;98:2289-92.
29. Wiedmann M, Libert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000;31:230-4.
30. Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I, et al. Immu-nogenicity of hepatitis Avaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1117-24.
31. Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr 2003;37:258-61.
32. Koksal Y, Yalcin B, Aydin GB, et al. Immunogenicity of hepatitis A vaccine in children with cancer. Pediatr Hematol Oncol 2006;23: 619-24.
33. Bell BP. Hepatitis Avaccine. Semin Pediatr Infect Dis 2002;13:165-73.
34. Schmidtke P, Habermehl P, Knuf M, et al. Cell mediated and antibody immune response to inactivated hepatitis A vaccine. Vaccine 2005; 23:5127-32.
35. Garner-Spitzer E, Kundi M, Rendi-Wagner P, et al. Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptors HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. Vaccine 2009;27:197-204.
36. Martinetti M, De Silvestri A, Belloni C, et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000;97:234-40.
37. Wang C, Tang J, Song W, et al. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004;39:978-88.